文献速递MDS 与骨髓增殖性肿瘤

2型钙网蛋白突变通过激活ATF6促进骨髓增殖性肿瘤中BCL-xL介导的生存

Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms.
PubMed 文献 · Blood · 2025-01-01

骨髓增殖性肿瘤中,2型钙网蛋白突变(CALRins5)因钙网蛋白伴侣功能丧失而激活未折叠蛋白反应的ATF6通路,该功能丧失由CALRins5突变C末端干扰关键伴侣残基H170所致;CALRins5细胞部分依赖ATF6实现细胞因子非依赖性生长,BCL-xL为ATF6的转录靶点,促进2型CALR突变细胞生存。

要点

  • CALRins5突变因CALR伴侣功能丧失而激活UPR的ATF6通路。
  • 该功能丧失由CALRins5突变C末端干扰关键伴侣残基H170所致。
  • CALRins5细胞部分依赖ATF6实现细胞因子非依赖性生长。

核心结论

  • CALRins5突变因CALR伴侣功能丧失而激活ATF6通路,CALRins5细胞部分依赖ATF6实现细胞因子非依赖性生长,BCL-xL为ATF6的转录靶点,促进2型CALR突变细胞生存。

研究设计与样本

  • 基础实验研究,比较CALRins5与CALRdel52突变对未折叠蛋白反应通路的激活与依赖差异。

主要发现

  • CALRins5突变因CALR伴侣功能丧失而激活UPR的ATF6通路。
  • 该功能丧失由CALRins5突变C末端干扰关键伴侣残基H170所致。
  • CALRins5细胞部分依赖ATF6实现细胞因子非依赖性生长。
  • BCL-xL为ATF6的转录靶点,促进2型CALR突变细胞生存。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most calreticulin (CALR) mutations in myeloproliferative neoplasms are classified as either type 1, a 52-base pair deletion (CALRdel52); or type 2, a 5-base pair insertion (CALRins5). Both are gain-of-function (GOF) mutations that generate an identical mutant C-terminal tail, which mediates the binding to, and activation of, the thrombopoietin receptor myeloproliferative leukemia protein (MPL). We recently reported that despite this shared GOF, CALRdel52 but not CALRins5 mutations cause loss of calcium binding function, leading to activation of, and dependency on, the inositol-requiring enzyme 1/X-box binding protein 1 pathway of the unfolded protein response (UPR). This led us to ask whether CALRins5 mutations activate and depend on a different UPR pathway, and whether this is likewise mediated by a mutation type-specific loss-of-function (LOF). Here, we show that CALRins5 mutations lead to activation of the activating transcription factor 6 (ATF6) pathway of the UPR due to loss of CALR chaperone function. This LOF is caused by interference of the CALRins5 mutant C terminus with key chaperone residue H170. Furthermore, we show that CALRins5 cells are partially dependent on ATF6 for cytokine-independent growth, and identify B-cell lymphoma extra large as a transcriptional target of ATF6 that promotes type 2 CALR-mutant cell survival.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Arellano NS, Heaton WL, Nauman MC, et al. Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms. Blood. 2025. PMID: 40403318. doi:10.1182/blood.2024026940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。